Literature DB >> 32978518

A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.

Kaiyu Qian1,2,3, Gang Wang2,3,4, Lingao Ju2,3,4, Jiyan Liu5, Yongwen Luo1, Yejinpeng Wang1, Tianchen Peng1, Fangjin Chen6, Yi Zhang7,8, Yu Xiao1,2,3,4, Xinghuan Wang9,10.   

Abstract

5-10% of total prostate cancer (PCa) cases are hereditary. Particularly, immune checkpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% of PCa cases, whereas genetic susceptibility genes remain completely unknown. We identified a Chinese family with two PCa patients, in which the PCa phenotype co-segregated with a rare germline variant EGFRR831H. Patient-derived conditionally reprogrammed cells (CRC) exhibited increased EGFR and AKT phosphorylation, and a sensitivity to EGFR antagonist Afatinib in migration assays, suggesting the EGFR allele was constitutively active. Both EGFRR831H-mutant tumours contained biallelic CDK12 inactivation, together with prominent tandem duplication across the genome. These somatic mutations could be detected in urine before surgery. Analysis of public databases showed a significant correlation between the mutation status of EGFR and CDK12. Taken together, our genetic and functional analyses identified a previously undescribed link between EGFR and PCa.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32978518     DOI: 10.1038/s41388-020-01476-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Familial prostate cancer.

Authors:  Veda N Giri; Jennifer L Beebe-Dimmer
Journal:  Semin Oncol       Date:  2016-08-18       Impact factor: 4.929

2.  Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.

Authors:  Veda N Giri; Sarah E Hegarty; Colette Hyatt; Erin O'Leary; John Garcia; Karen E Knudsen; William K Kelly; Leonard G Gomella
Journal:  Prostate       Date:  2018-11-18       Impact factor: 4.104

Review 3.  Prostate cancer.

Authors:  Gerhardt Attard; Chris Parker; Ros A Eeles; Fritz Schröder; Scott A Tomlins; Ian Tannock; Charles G Drake; Johann S de Bono
Journal:  Lancet       Date:  2015-06-11       Impact factor: 79.321

4.  Germline genetic variants in men with prostate cancer and one or more additional cancers.

Authors:  Patrick G Pilié; Anna M Johnson; Kristen L Hanson; Megan E Dayno; Ashley L Kapron; Elena M Stoffel; Kathleen A Cooney
Journal:  Cancer       Date:  2017-06-28       Impact factor: 6.860

5.  EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.

Authors:  Shun Lu; Yongfeng Yu; Ziming Li; Ruoying Yu; Xue Wu; Hairong Bao; Yan Ding; Yang W Shao; Hong Jian
Journal:  J Thorac Oncol       Date:  2019-01-02       Impact factor: 15.609

6.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.

Authors:  Xuefeng Liu; Ewa Krawczyk; Frank A Suprynowicz; Nancy Palechor-Ceron; Hang Yuan; Aleksandra Dakic; Vera Simic; Yun-Ling Zheng; Praathibha Sripadhan; Chen Chen; Jie Lu; Tung-Wei Hou; Sujata Choudhury; Bhaskar Kallakury; Dean G Tang; Thomas Darling; Rajesh Thangapazham; Olga Timofeeva; Anatoly Dritschilo; Scott H Randell; Christopher Albanese; Seema Agarwal; Richard Schlegel
Journal:  Nat Protoc       Date:  2017-01-26       Impact factor: 13.491

Review 7.  Screening for familial and hereditary prostate cancer.

Authors:  Henry T Lynch; Omofolasade Kosoko-Lasaki; Stephen W Leslie; Marc Rendell; Trudy Shaw; Carrie Snyder; Anthony V D'Amico; Sarah Buxbaum; William B Isaacs; Stacy Loeb; Judd W Moul; Isaac Powell
Journal:  Int J Cancer       Date:  2016-02-05       Impact factor: 7.396

8.  CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.

Authors:  Yeqing Yuan; Zhengzuo Sheng; Zhenhua Liu; Xiaowei Zhang; Yunbei Xiao; Jing Xie; Yixiang Zhang; Tao Xu
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

9.  Comprehensive genomic profiling of urothelial carcinoma cell lines reveals hidden research bias and caveats.

Authors:  Yongwen Luo; Lingao Ju; Gang Wang; Chen Chen; Yejinpeng Wang; Liang Chen; Yi Zhang; Yu Xiao; Xinghuan Wang
Journal:  Clin Transl Med       Date:  2020-01

10.  The long tail of oncogenic drivers in prostate cancer.

Authors:  Joshua Armenia; Stephanie A M Wankowicz; David Liu; Jianjiong Gao; Ritika Kundra; Ed Reznik; Walid K Chatila; Debyani Chakravarty; G Celine Han; Ilsa Coleman; Bruce Montgomery; Colin Pritchard; Colm Morrissey; Christopher E Barbieri; Himisha Beltran; Andrea Sboner; Zafeiris Zafeiriou; Susana Miranda; Craig M Bielski; Alexander V Penson; Charlotte Tolonen; Franklin W Huang; Dan Robinson; Yi Mi Wu; Robert Lonigro; Levi A Garraway; Francesca Demichelis; Philip W Kantoff; Mary-Ellen Taplin; Wassim Abida; Barry S Taylor; Howard I Scher; Peter S Nelson; Johann S de Bono; Mark A Rubin; Charles L Sawyers; Arul M Chinnaiyan; Nikolaus Schultz; Eliezer M Van Allen
Journal:  Nat Genet       Date:  2018-04-02       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.